Seletracetam enhances short term depression in vitro

Xiaofeng Yang, Anna L. Meehan, Steven M. Rothman, Janet M Dubinsky

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Seletracetam (SEL), an analog of the antiepileptic drug levetiracetam (LEV), decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A with a higher affinity than LEV. Experiments were performed to determine if SEL, like LEV, reduces the later EPSPs in long trains of stimuli in a manner dependent upon access to the interior of synaptic vesicles and SV2A binding. When hippocampal slices were incubated in 3-30. μM SEL for 3. h, but not 30. min, the relative amplitude of the CA1 field excitatory synaptic potentials decreased over the course of a train of high frequency stimuli more than for control slices. This short term depression was frequency and dose dependent and largely disappeared when the spontaneous activity during the loading period was removed by cutting the Schaffer collaterals. The SEL effect was also observed in slices loaded during prolonged stimulation at 1. Hz, but not 10. Hz. Hippocampal slices loaded with both SEL and FM1-43 to visualize synaptic boutons released the FM1-43 in response to prolonged stimulation much more slowly than control slices during prolonged stimulation. Like LEV, SEL produced a frequency-dependent decrement of synaptic transmission that was dependent upon the drug entering recycling synaptic vesicles and compatible with SV2A binding. Previous observations of SV2A binding affinity correlated with the current effect of SEL and the previously reported effect of LEV on synaptic transmission validate SV2A as an extremely attractive target for future antiepileptic drug development.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalEpilepsy Research
StatePublished - Nov 2015

Bibliographical note

Funding Information:
We thank Drs. Manuel Esguerra, Isabelle Niespodziany and Christian Wolff for critical reading of the manuscript. This work was supported by a grant from UCB Pharma, Belgium . The funder did not limit experimental design or contribute to data analysis or interpretation other than the suggestions for wording changes that improved readability received from Drs. Niespodziany and Wolff.

Publisher Copyright:
© 2015 Elsevier B.V.


  • Anticonvulsants
  • Antiepileptic drugs
  • Epilepsy
  • Levetiracetam
  • SV2A
  • Seletracetam
  • Synaptic vesicles


Dive into the research topics of 'Seletracetam enhances short term depression in vitro'. Together they form a unique fingerprint.

Cite this